# Alexis Yongmei Ji

> Alexis Yongmei Ji is a Series A investor at Life Science Venture Capital Management backing Biotechnology. See 6 investments, round sizes, portfolio and…

- Type: Angel Investor
- Fund: [Life Science Venture Capital Management](https://shizune.co/investors/profile/life-science-venture-capital-management)
- Location: San Francisco, United States
- Total investments: 6
- Last investment: Sep 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/yongmeiji

Alexis Yongmei Ji is a Venture investor at Life Science Venture Capital.

## Contacts

5 contacts available for Alexis Yongmei Ji: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/alexis-yongmei-ji?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical Device | 2 | 33% |
| Medical | 1 | 17% |
| Oncology | 1 | 17% |
| Health Care | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Walking Fish Therapeutics | Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies. | $50M | Series A | Sep 13, 2021 |  |
| NanoCellect Biomedical | NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $20M | Series D | Aug 13, 2021 |  |
| NanoCellect Biomedical | NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $15M | Series C | Feb 01, 2021 |  |
| Actym Therapeutics, Inc. | Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies,STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures. | $34M | Series A | Apr 27, 2020 |  |
| NanoCellect Biomedical | NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $250K |  | Jan 12, 2018 |  |
| NanoCellect Biomedical | NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $10M | Series B | Nov 29, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Vertical Venture Partners](https://shizune.co/investors/profile/vertical-venture-partners) — VC Fund, 4 deals together
- [FusionX Ventures](https://shizune.co/investors/profile/fusionx-ventures) — VC Fund, 3 deals together
- [Anzu Partners](https://shizune.co/investors/profile/anzu-partner) — VC Fund, 2 deals together
- [Sagian Equity](https://shizune.co/investors/profile/sagian-equity) — VC Fund, 2 deals together
- [Genoa Ventures](https://shizune.co/investors/profile/5-prime-ventures) — VC Fund, 1 deal together
- [Agilent Technologies](https://shizune.co/investors/profile/agilent) — VC Fund, 1 deal together

## About Life Science Venture Capital Management

VC Fund

Life Science Venture Capital Management

1 contacts available at Life Science Venture Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Alexis Yongmei Ji | Venture investor | https://shizune.co/investors/profile/alexis-yongmei-ji |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alexis Yongmei Ji invest in?

Alexis Yongmei Ji invests primarily in Biotechnology, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alexis Yongmei Ji?

Public channels for Alexis Yongmei Ji include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Alexis Yongmei Ji last invest?

The most recent investment recorded for Alexis Yongmei Ji closed in Sep 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co